Cullinan Management (CGEM) AI Stock Analysis

• Market Cap: $445.28M
• Dividend Yield: N/A
• Average Volume (3M): 476.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.27
• Revenue Growth: N/A
• EPS Growth: 15.34%
• Country: US
• Employees: 111
• Sector: Healthcare
• Sector Strength: 72
• Industry: Biotechnology
• EPS (TTM): -3.13
• Shares Outstanding: 58,512,825
• 10 Day Avg. Volume: 575,329
• 30 Day Avg. Volume: 476,916
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 936.21
• Price to Cash Flow (P/CF): -3.40
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $33.33
• Price Target Upside: 322.43% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

Cullinan Management's overall stock score reflects significant financial and operational challenges, marked by negative profitability and cash flow concerns. However, the recent milestone in their cancer trial introduces a potential positive catalyst for future growth. Technical indicators suggest caution, with the current bearish trend indicating further downside risk. While the corporate event provides optimism, the company’s financial health remains a critical concern.

Positive Factors

Market Position

CLN-978 is the only CD19-targeted T-cell engager currently in clinical development, highlighting its unique position in the market.

Regulatory Approval

The EMA has approved Cullinan's Clinical Trial Application for the Phase 1 trial of CLN-978 in rheumatoid arthritis, clearing the way for trial initiation.

Targeting Strategy

Positive Phase 3 data from Amgen's Uplizna in generalized myasthenia gravis suggest a broad application of targeting CD19, which benefits Cullinan's prospects.

Negative Factors

Development Timelines

Cullinan remains focused on the development of CLN-978 in systemic lupus erythematosus and rheumatoid arthritis, expecting initial data from trials in 2025.

Market Competition

Both Amgen's Uplizna and Cullinan's CD19xCD3 T cell engager (CLN-978) showed B cell depletion to equivalent levels past 150 days, indicating a potent asset for Cullinan.

Pipeline Expansion

Cullinan is working to expand the trial into additional geographies, which could enhance the study's impact and reach.

Cullinan Management Business Overview & Revenue Model

Company Description

Cullinan Oncology, Inc. (CGEM) is a clinical-stage biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies. The company operates in the biotechnology sector and is dedicated to advancing its portfolio of novel cancer treatments to address unmet medical needs. Cullinan leverages a rigorous scientific approach to discover and develop innovative therapies that target specific cancer pathways.

How the Company Makes Money

Cullinan Oncology generates revenue primarily through strategic partnerships, collaborations, and licensing agreements with other pharmaceutical companies. These partnerships often involve milestone payments, royalties, and research funding, providing financial resources to advance their drug development programs. Additionally, Cullinan may earn revenue from out-licensing its pipeline candidates to commercial partners who have the capability to bring these therapies to market. The company's focus on developing promising oncology treatments positions it for potential future revenue from successful drug approvals and commercialization.

Cullinan Management Financial Statement Overview

Summary

Cullinan Management faces considerable financial challenges, with negative profitability and cash flow metrics. While the balance sheet maintains equity strength, the lack of revenue and ongoing losses indicate operational and sustainability risks. The company's heavy reliance on external financing underscores the need for strategic improvements to achieve financial stability.

Income Statement

Cullinan Management's income statement reveals significant challenges, with consistent negative net income and EBIT over the years and no revenue for the recent periods. The TTM (Trailing-Twelve-Months) data shows a substantial net loss, indicating persistent operational difficulties. The lack of revenue growth and negative profit margins highlight severe profitability issues.

Balance Sheet

The balance sheet shows a strong equity position, with stockholders' equity consistently higher than total debt, leading to a favorable debt-to-equity ratio. However, the company faces potential risks with its high liabilities relative to its total assets. The equity ratio remains stable, but the absence of revenue poses a long-term sustainability risk.

Cash Flow

The cash flow statement highlights negative free cash flow and operating cash flow trends, indicating cash burn concerns. The financing activities have been a primary source of cash, suggesting reliance on external funding. The inability to generate positive cash flow from operations poses a significant risk to financial health.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	18.94M	0.00	0.00
	Gross Profit
-153.00K	-310.00K	-93.00K	18.89M	-62.00K	-70.00K
	EBIT
-196.92M	-191.09M	144.65M	-67.95M	-60.34M	-22.27M
	EBITDA
-196.61M	-190.34M	151.41M	-67.90M	-60.27M	-22.20M
	Net Income Common Stockholders
-167.38M	-153.16M	111.21M	-65.04M	-50.85M	-20.04M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
398.98M	467.07M	550.12M	430.86M	210.21M	98.63M
	Total Assets
621.82M	484.18M	561.12M	437.19M	214.71M	100.46M
	Total Debt
2.15M	3.59M	5.19M	0.00	0.00	0.00
	Net Debt
-80.85M	-94.84M	-544.93M	-430.86M	-168.20M	-63.25M
	Total Liabilities
31.50M	30.29M	26.09M	11.81M	291.05M	140.37M
	Stockholders Equity
590.33M	453.70M	535.03M	422.58M	-77.64M	-40.77M
Cash Flow		Free Cash Flow
-145.30M	-134.48M	-127.80M	-44.02M	-29.78M	-20.92M
	Operating Cash Flow
-145.30M	-134.28M	-126.66M	-43.43M	-29.77M	-20.90M
	Investing Cash Flow
-136.31M	35.81M	248.97M	-333.77M	-5.42M	-35.40M
	Financing Cash Flow
266.19M	40.75M	-25.93M	268.78M	140.14M	85.72M

Cullinan Management Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.89
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGEM, the sentiment is Negative. The current price of 7.89 is above the 20-day moving average (MA) of 7.81, below the 50-day MA of 8.52, and below the 200-day MA of 13.57, indicating a neutral trend. The MACD of -0.27 indicates Negative momentum. The RSI at 47.25 is Neutral, neither overbought nor oversold. The STOCH value of 73.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CGEM.

Cullinan Management Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	50 Neutral	$5.51B	2.95	-43.70%	2.78%	16.94%	3.59%
ARVN	46 Neutral	$591.44M	―	-35.41%	―	-39.92%	7.38%
KURA	45 Neutral	$464.47M	―	-42.91%	―	―	2.90%
IMTX	45 Neutral	$499.57M	52.85	3.73%	―	188.64%	―
BCYC	43 Neutral	$517.27M	―	-29.06%	―	30.27%	44.12%
CGEM	42 Neutral	$445.28M	―	-32.06%	―	―	15.34%
URGN	36 Underperform	$445.73M	―	-452.20%	―	9.29%	13.49%

Cullinan Management Corporate Events

Cullinan Management Achieves Milestone in Cancer Trial

On January 28, 2025, Cullinan Therapeutics, in collaboration with Taiho Pharmaceutical and Taiho Oncology, announced that their REZILIENT1 trial successfully met its primary endpoint of overall response rate. The trial involved zipalertinib monotherapy for patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations. The results, consistent with previous data presentations, are from the Phase 2b part of the study, with plans to present full results at an upcoming international medical conference. The companies intend to seek U.S. regulatory approval in the latter half of 2025.